

Bacteremia, Causative Agents and Antimicrobial Susceptibility Among HIV-1–infected Children on Antiretroviral Therapy in Uganda and Zimbabwe

Victor Musiime, MMED,* Adrian Cook, MSc,† Sabrina Bakeera-Kitaka, MMED,‡§ Tichaona Vhembo, MBChB,¶ Joseph Lutakome, MBChB,|| Rosette Keishanyu, MMED,* Andrew J. Prendergast, DPhil,† Sam Lubwama, Dip MLT,* Val Robertson, MSc,¶ Peter Hughes, MSc,|| Kusum Nathoo, MSc,¶ Paula Munderi, FRCP,|| Nigel Klein, PhD,** Philippa Musoke, PhD,‡§ and Diana M. Gibb, MSc,† on Behalf of the ARROW Trial Team

Background: Bacteremia is common in HIV-infected children in Africa, including after start of antiretroviral therapy (ART), but there are limited data on causative pathogens and their antimicrobial sensitivity patterns in this population.

Methods: We analyzed data on blood cultures taken from HIV-infected children developing acute febrile illness after enrollment to the Antiretroviral Research for Watoto (ARROW) clinical trial in Uganda and Zimbabwe. Patterns of bacterial pathogens and their antimicrobial susceptibilities were determined and bacteremia rates calculated over time from ART initiation.

Results: A total of 848 blood cultures were obtained from 461 children, of which 123 (14.5%) from 105 children (median age 3.5 years, 51% girls) were culture positive, including 75 (8.8%) with clearly pathogenic organisms. The event rates for positive cultures with clearly pathogenic organisms after 0–1, 2–3, 4–11 and ≥12 months on ART were 13.3, 11.4, 2.1 and 0.3 per 1000 person-months of follow-up, respectively. The pathogens isolated (n; %) were *Streptococcus pneumoniae* (36; 28.3%), *Staphylococcus aureus* (11; 8.7%), *Klebsiella pneumoniae* (6; 4.7%), *Pseudomonas aeruginosa* (6; 4.7%), *Salmonella* spp (6; 4.7%), *Escherichia coli* (5; 3.9%), *Haemophilus influenzae* (1; 0.8%) and fungal spp (4; 3.1%). Other bacteria of doubtful pathogenicity (n = 52; 42%) were also isolated. Most isolates tested were highly (80–100%) susceptible to ceftriaxone, cefotaxime and ciprofloxacin; very few (~5%) were susceptible to cotrimoxazole; *S. pneumoniae* had high susceptibility to amoxicillin/ampicillin (80%).

Conclusions: Rates of proven bacteremia were >20-fold higher immediately after starting ART compared with 12 months later in African HIV-infected children. *S. pneumoniae* was most commonly isolated, suggesting need for pneumococcal vaccination and effective prophylactic antibiotics.

Key Words: bacteremia, HIV, children, Africa

(*Pediatr Infect Dis J* 2013;32: 856–862)

Accepted for publication February 07, 2013.

From the *Joint Clinical research Center, Kampala, Uganda; †Medical Research Council, Clinical Trials Unit, London, United Kingdom; ‡Mulago Hospital, Paediatric Infectious Diseases Clinic/ Baylor-Uganda; §Department of Paediatrics and Child health, Makerere University, College of Health Sciences, Kampala, Uganda; ¶University of Zimbabwe, College of Health Sciences, Harare, Zimbabwe; ||Medical Research Council/Uganda Virus Research Institute, Entebbe, Uganda; and **Institute of Child Health, University College London, London, United Kingdom.

ARROW is funded by the UK Medical Research Council and the UK and Department for International Development. First-line drugs are provided by GlaxoSmithKline. The authors have no other funding or conflicts of interest to disclose.

Address for correspondence: Victor Musiime, MMED, Joint Clinical Research Center, Plot 101 Lubowa Estates, off Entebbe road, P.O. Box 10005 Kampala, Uganda. E-mail: musiiimev@yahoo.co.uk.

Copyright © 2013 by Lippincott Williams & Wilkins

ISSN: 0891-3668/13/3208-0856

DOI: 10.1097/INF.0b013e31828c3991

HIV-infected children are at increased risk of acquiring and dying from bacteremia.^{1–8} Although antiretroviral therapy (ART) has reduced the incidence,^{9–11} the burden of bacteremia remains high in HIV-infected compared with HIV-uninfected children, especially in the first 3 months on ART.^{12,13} Studies in Kenya and South Africa reported that the most commonly isolated pathogens in HIV-infected children with bacteremia were *Streptococcus pneumoniae*, *Staphylococcus aureus* and Enterobacteriaceae.^{12,14,15} In Uganda and Zimbabwe, the most common pathogens isolated from HIV-infected and uninfected hospitalized children (many with severe acute malnutrition) were *Salmonella* spp, *Escherichia coli*, *S. aureus* and *S. pneumoniae*.^{1,5,16}

Bacterial isolates have been reported to have high rates of resistance to commonly used antibiotics in sub-Saharan Africa, such as cotrimoxazole, ampicillin, chloramphenicol and gentamicin. Furthermore, Enterobacteriaceae have been identified as extended-spectrum β -lactamase (ESBL) producers in several studies, implying that they would be resistant to third generation cephalosporins.^{1,14,16} These data are worrying, given the limited range of antibiotic options in most sub-Saharan African countries.

Data from sub-Saharan Africa are very limited on both the pathogens and antimicrobial susceptibility patterns among ART-treated HIV-infected children with bacteremia. We therefore set out to investigate these factors in a large cohort of HIV-infected children who initiated ART in the Antiretroviral Research for Watoto (ARROW) trial in Uganda and Zimbabwe.

MATERIALS AND METHODS

Study Subjects

This analysis used data from the ongoing ARROW clinical trial (ISCRTN 24791884; www.arrowtrial.org), a randomized factorial trial of 2 clinical monitoring strategies and 3 antiretroviral drug treatment strategies at 3 clinical sites in Uganda and 1 in Zimbabwe. HIV-1 infected, ART-naive (except for prior infant antiretroviral drug prophylaxis of mother-to-child transmission of HIV) children ages 3 months to 17 years were randomized into 3 ART regimen arms: abacavir, lamivudine (3TC) and a non-nucleoside reverse transcriptase inhibitor in the first arm; abacavir, 3TC, non-nucleoside reverse transcriptase inhibitor and zidovudine in arms 2 and 3, with zidovudine in arm 2 and the non-nucleoside reverse transcriptase inhibitor in arm 3 being dropped after 9 months, as per the trial protocol. Children were reviewed in the clinic every 4–6 weeks, and each had CD4 count/percentage, complete blood counts, liver and renal function tests done every 12 weeks. If a child developed any illness, the caregiver was encouraged to return to the study clinic for evaluation and management; all children had access to hospitalization if required. If treated in centers other than study clinics, caregivers were asked to bring treatment forms at the next scheduled visit.

The large majority of children (1199/1206; 99.4%) were receiving cotrimoxazole prophylaxis at enrollment (started at screening in those newly diagnosed with HIV) and took it until at least 96 weeks after ART initiation; thereafter, 760 of 1002 (75.8%) children were randomized to continue or to stop cotrimoxazole a median of 108 (range 96, 144) weeks after ART initiation, as an additional randomization and as per the amended trial protocol. Children who developed febrile illnesses during follow-up had investigations that included blood culture and antibiotic sensitivity testing.

Blood Culture and Sensitivity Testing

Blood culture and sensitivity testing were done in 3 laboratories: 2 in Uganda (Joint Clinical Research Centre and Medical Research Council/Uganda Virus Research Institute [MRC/UVRI]) and 1 (UZ-CHS) in Zimbabwe. At the Joint Clinical Research Centre laboratory, bacterial isolation and typing as well as antimicrobial susceptibility testing were undertaken using the automated Becton Dickinson Bactec system (www.bd.com) with incubation of a targeted 1–3 mL of blood for 7 days.¹⁷ Positive cultures were subcultured on blood agar, MacConkey agar and chocolate agar. After overnight incubation, isolates were identified and antimicrobial susceptibility (including the minimum inhibitory concentration) was determined using the Phoenix Becton Dickinson Microbiology Systems. In particular, ESBL-producing bacteria were identified on the Phoenix Becton Dickinson instrument following the manufacturer's recommendations.¹⁸ Interpretation and reporting of all susceptibility testing results were in accordance with the Clinical Laboratory Standard Institute, United States (www.clsi.org) guidelines.¹⁹ At the MRC/UVRI laboratory, bacterial isolation was undertaken using the Bactec 9120 blood system with incubation of a targeted 1–3 mL of blood for 7 days. Positive cultures were subcultured onto blood agar, chocolate agar and MacConkey agar plates. Isolated organisms were identified using serological and biochemical tests such as the Analytical Profile Index system,²⁰ the Staphylase test and the streptococcal grouping test. Antimicrobial susceptibility was undertaken using the Kirby–Bauer method.²¹ Antibiotic-impregnated paper discs were used to test whether bacteria were susceptible to specific antibiotics. Zone diameters of inhibition around the antibiotic discs were measured in millimeters and interpreted according to British Society of Antimicrobial Chemotherapy (www.bsac.org.uk) guidelines.²² At the UZ-CHS laboratory, bacterial isolation was done using manual methods. In this case, a targeted 1–3 mL blood was inoculated into pediatric blood culture bottles containing 10-mL tryptone soy broth and incubated for 10 days at 37°C, culturing at days 1, 5 and 10 onto blood, chocolate and MacConkey agars. Isolated organisms were identified using standard manual techniques including Gram stain, biochemical tests, Streptex and Analytical Profile Index systems. Susceptibility testing was done using the Clinical Laboratory Standard Institute¹⁹ method for disc susceptibility testing using *E. coli* American Type Culture Collection 25922, *S. aureus* American Type Culture Collection 25923 and *Pseudomonas aeruginosa* American Type Culture Collection 27853 as controls.

Ethical Review

All caregivers of study participants gave written informed consent, and children of ages 13 years and above, all aware of their HIV status, gave written informed assent. The study protocol was approved by the ethics review committee/Institution Review Board of each participating center and by the International Ethics Committee of University College, London, United Kingdom.

Statistical Analyses

Characteristics of children with or without isolation of pathogens were compared using *t* tests and chi-square tests. The event

rate of positive cultures was calculated using person-time on ART. Descriptive statistics were used to demonstrate the pathogens identified and their antibiotic susceptibilities. All analyses were done using Stata v12.0. (StataCorp LP, College Station, TX).

RESULTS

A total of 1206 children were enrolled in the ARROW trial between March 2007 and November 2008 and continued follow-up to March 2012, but with bacteremia data evaluated up to July 2011. Their median age was 6 years, 31% were under 3 years and there were approximately equal numbers of boys and girls (Table 1). Most participants had advanced HIV disease at enrollment, 71% had World Health Organization (WHO) stage 3 or 4 disease and 65% had CD4 cell percentage below 15%.

Investigation of febrile illness included blood cultures in 461 children, of median age 4.4 years; 52% were female (Table 1). The children who had blood cultures performed were significantly younger than other trial participants (median age 4.4 versus 6.9 years, $P < 0.001$) and more likely to have WHO stage 4 conditions (19% versus 11%, $P = 0.002$). However, there were no significant differences in CD4 cell count or percentage or in weight-for-age or height-for-age Z scores at ART initiation (Table 1). Each child experienced a median of 4 episodes of fever, and a total of 848 blood cultures were performed during 6704 febrile episodes. Pathogens were isolated in 123 cultures (14.5%), from 105 children. Four samples had 2 different pathogens isolated, resulting in a total of 127 isolates. The 105 children with bacterial isolates had a median age of 3.5 years; 76% had WHO stage 3 or 4 and 65% had CD4% <15%; their mean weight-for-age and height-for-age Z scores were -2.73 and -2.64 , respectively, at enrollment; they did not significantly differ from children without bacterial isolates, as shown in Table 1.

Incidence of Bacteremia

The incidence rate of all positive cultures (both pathogenic and those of doubtful pathogenicity) was highest in the first 3 months after ART initiation (Table 2). In the first month on ART, there were 23 positive cultures in 1202 person-months of observation, an event rate of 19.1 per 1000 person-months. With more time on ART, fewer positive cultures were observed, with the event rate dropping to 13.5, 3.62 and 0.74 per 1000 person-months at 1–<3, 3–<12 and ≥ 12 months post-ART initiation, respectively (Table 2). When only clearly pathogenic isolates were considered (ie, excluding pathogens of doubtful pathogenicity), the respective event rates dropped to 13.3, 11.4, 2.1 and 0.3 per 1000 person-months at 0–<1, 1–<3, 3–<12 and ≥ 12 months post-ART initiation (Table 2). Of 123 bacteremia episodes, 60 (49%) were hospitalized and 9 (7%) resulted in death within 28 days of taking the blood sample.

The culture positivity rate in Harare, Zimbabwe (31/109; 28%), was significantly higher than at the Ugandan sites (MRC Entebbe 10/64, 16%; Joint Clinical Research Center Kampala 46/408, 11%; Mulago Paediatric Infectious Diseases Clinic 36/267, 13%), $P < 0.0001$.

Bacterial Pathogens Isolated

Pathogenic Bacteria

S. pneumoniae was the most commonly isolated pathogen ($n = 36$, 28%). Other frequently isolated pathogenic organisms included: *S. aureus* ($n = 11$, 9%), *Klebsiella pneumoniae* ($n = 6$, 5%), *P. aeruginosa* ($n = 6$, 5%), *Salmonella* spp ($n = 6$, 5%) and *E. coli* ($n = 5$, 4%) (Fig. 1A). Of note, there was only 1 isolate of *Haemophilus influenzae*; typing was not undertaken. Fungal spp were isolated in 4 cases (3%).

TABLE 1. Participant Characteristics

		Specimen Cultured			Pathogen Isolated*		P
		All n (%)	No n (%)	Yes n (%)	No n (%)	Yes n (%)	
Total		1206 (100%)	745 (62%)	461 (38%) (461 = 356 + 105)	356 (77%)	105 (23%)	
Sex	Male	596 (49%)	375 (50%)	221 (48%)	170 (48%)	51 (49%)	0.88
	Female	610 (51%)	370 (49%)	240 (52%)	186 (52%)	54 (51%)	
Age	Yr [†]	6.0 (2.4, 9.3)	6.9 (2.9, 9.7)	4.4 (1.8, 8.6)	4.7 (1.8, 8.8)	3.5 (1.9, 7.9)	0.29
	<3 yr	370 (31%)	191 (26%)	179 (39%)	134 (38%)	45 (43%)	
WHO stage	1/2	354 (30%)	218 (29%)	136 (30%)	121 (31%)	25 (24%)	0.48
	3	682 (57%)	443 (59%)	239 (51%)	181 (51%)	58 (55%)	
	4	170 (14%)	84 (11%)	86 (19%)	64 (18%)	22 (21%)	
CD4%	Median	12	13	12	11	13	0.17
	IQR	7, 17	8, 18	7, 16	7, 16	8, 17	
	Range	0, 49	0, 49	0, 46	0, 46	0, 37	
	≥15%	424 (35%)	276 (37%)	148 (32%)	112 (31%)	36 (34%)	0.44
	≥10%, <15%	336 (28%)	205 (28%)	131 (28%)	97 (27%)	34 (32%)	
	≥5%, <10%	244 (20%)	151 (20%)	93 (20%)	77 (22%)	16 (15%)	
	<5%	202 (17%)	113 (15%)	89 (19%)	70 (20%)	19 (18%)	
CD4 [‡] count	Median	355	343	392	389	394	0.48
	IQR	175, 685	183, 657	159, 746	146, 750	188, 746	
	Range	1, 4458	1, 4458	1, 4237	1, 3543	3, 4237	
Weight-for-age	Z score [‡]	-2.43 (1.62)	-2.30 (1.52)	-2.63 (1.76)	-2.60 (1.66)	-2.73 (2.07)	0.53
Height-for-age		-2.39 (1.42)	-2.34 (1.35)	-2.47 (1.52)	-2.42 (1.47)	-2.64 (1.67)	

*All those with specimen cultured.

[†]Median (IQR).[‡]Mean (standard deviation), using UK 1990 reference data.

IQR indicates interquartile range.

Bacteria of Doubtful Pathogenicity

Other isolated organisms (n = 52, 41%), shown in Figure 1B, which were classified as being of doubtful pathogenicity, included: staphylococcal spp other than *S. aureus* (including *Staphylococcus haemolyticus* and *Staphylococcus hominis*; n = 12, 9%); streptococcal spp other than *S. pneumoniae* (including *Streptococcus viridans* and *Streptococcus mitis*; n = 10, 8%); and other bacteria including *Enterococcus* spp (n = 4, 3%), *Corynebacteria* spp (n = 3, 2%), *Moraxella* spp (n = 2, 1.5%) and *Providentia* spp (n = 2, 1.5%).

Antimicrobial Susceptibility Patterns

We considered susceptibility rates of <50% as low, those 50–79% as moderate and those ≥80% as high. Among *S. pneumoniae* isolates, there were low rates of susceptibility to cotrimoxazole (5%), moderate levels to penicillin G (58%) but high levels to amoxicillin/ampicillin (80%) and erythromycin (89%) (Table 3). All the *S. pneumoniae* isolates were susceptible to ceftriaxone, cefotaxime, chloramphenicol and cefuroxime. Of note, the 4 isolates that were resistant to amoxicillin/ampicillin

TABLE 2. Bacteremia Event Rates Among Children Who Developed Febrile Illnesses in Follow-up

Months on ART	0–<1	1–<3	3–<12	≥12	Total
Children in follow-up, n (%)	1206(100%)	1194(100%)	1179(100%)	1156(100%)	1206(100%)
Person-months follow-up	1202	2371	10,498	40,633	54,704
Febrile episodes, n	651	738	1659	3656	6704
Number of cultures					
Total cultures, n	143	152	291	262	848
Children with culture, n (%)	130(11%)	128(11%)	209(18%)	193(17%)	461(38%)
Total positive cultures, n	23	32	38	30	123
Children with positive culture, n (%)	23(1.9%)	28(2.3%)	35(3.0%)	29(2.5%)	105(8.7%)
Positive culture incidence rate per 1000 mo					
All isolates, rate (n)	19.13 (23)	13.50 (32)	3.62 (38)	0.74 (30)	2.25 (123)
Pathogenic isolates*	13.31 (16)	11.39 (27)	2.09 (22)	0.25 (10)	1.37 (75)
<i>Streptococcus pneumoniae</i>	6.66(8)	5.48(13)	1.24 (13)	0.05(2)	0.07(36)
<i>Staphylococcus aureus</i>	2.50(3)	2.53(6)	0.10(1)	0.02(1)	0.02(11)
<i>Salmonella</i> spp, <i>Escherichia coli</i> , <i>Pseudomonas aeruginosa</i> , <i>Klebsiella pneumoniae</i>	4.16(5)	2.53(6)	0.57(6)	0.15(6)	0.04(23)
Fungal spp	0.0(0)	0.42(1)	0.19(2)	0.02(1)	0.01(4)
CD4 cell % [‡]					
Children with CD4%	1164(100%)	1137(100%)	1170(100%)	1155(100%)	1206(100%)
CD4 % < 15%, n (%)	723(62%)	320(28%)	262(22%)	162(14%)	782(65%)
CD4 cell count per μL [‡]					
Children with CD4	1164(100%)	1137(100%)	1170(100%)	1155(100%)	1206(100%)
CD4 count < 200, n (%)	351(30%)	172(15%)	142(12%)	137(12%)	426(35%)

*All isolates, excluding other streptococcal spp, other staphylococcal spp and other bacteria.

[‡]CD4 tests were done routinely every 12 weeks: those in the 0–<1 month were taken at enrolment; 1–3 months at week 12; in the subsequent time periods several were taken at 12 weekly intervals.




FIGURE 1. Relative frequency of organisms isolated from HIV-infected children with bacteraemia (N = 127).

were susceptible to ceftriaxone, cefotaxime, vancomycin and erythromycin.

For other organisms, the numbers tested were small. However, low susceptibility rates to cotrimoxazole were observed among nearly all isolates. *S. aureus*, *E. coli* and *Salmonella* spp were also largely resistant to ampicillin/ amoxicillin (Table 3) but were highly susceptible to ceftriaxone, ciprofloxacin and meropenem. Of note, *K. pneumoniae* isolates, 60% of which were ESBL producers, were all resistant to ceftriaxone, cefotaxime, gentamicin and ampicillin/amoxicillin, but susceptible to amikacin, ciprofloxacin and meropenem. Of the 6 *K. pneumoniae* isolates, only 2 (33%) children had been hospitalized within a 7-day window either side of the date of the positive sample.

DISCUSSION

HIV-infected African children have high rates of bacteremia, even on ART, and especially in the first 3 months after ART initiation.^{12,13} Among children who developed febrile illnesses while on ART in our study, 14.5% of blood cultures were positive for bacterial pathogens, with *S. pneumoniae* observed in nearly one-third of the isolates. Positive cultures were around 20-fold more likely to occur in the first 3 months on ART compared with after 12 months on ART. The rate of conducting blood cultures per febrile episode was relatively constant across the observation periods in the first year on ART in our study, at 22%, 21%, 18% and 19% during the 0–<1 month, 1–<3 months, 3–<12 months and overall, respectively;

subsequently the rate dropped to 7%. Although this may have contributed to the lower rate of bacteremia after the first year on ART, higher rates of bacteremia during the first 3 months on ART were similarly observed in South Africa.¹² This pattern of high rates of bacterial infections contributed substantially to the high early morbidity and often mortality observed both in children in ARROW and adults in the Development of Antiretroviral Therapy in Africa trial.²³ In both trials, the mortality risk increased from enrolment to a maximum between days 30 and 50, then declined rapidly to day 180 before declining further but more slowly throughout the rest of the first year on ART.²⁴ The mortality risk was higher at lower CD4 counts/percentages, and the majority of deaths in both children and adults were deemed by independent review to be due to bacterial infections (mainly septicemia/meningitis). The bacteremia episodes in our study resulted in a 49% hospitalization rate and a 28-day mortality of 7%. This mortality is slightly higher than the 4.7% mortality associated with gram-negative bacteremia in Singapore,²⁵ but much lower than the 53% and 24% mortality rates observed with hospital-acquired and community-acquired bacteremia, respectively, in Kenya.²⁶

S. pneumoniae has always been the most common reported isolate among HIV-infected children with bacteremia.^{12,15} *S. pneumoniae* infections in HIV-infected children tend to be severe and are associated with high mortality.^{2,6,8} From studies in both resource-limited and well-resourced countries, the incidence of invasive pneumococcal disease among HIV-infected adults and

TABLE 3. Antimicrobial Susceptibility of Isolated Bacteria

Antibiotic*	Antibiotic Susceptibility of Isolated Pathogens Number Susceptible/Number Tested (%)					
	<i>Streptococcus pneumoniae</i>	<i>Staphylococcus aureus</i>	<i>Salmonella</i> spp	<i>Escherichia coli</i>	<i>Pseudomonas aeruginosa</i>	<i>Klebsiella pneumoniae</i>
Ceftriaxone	26/26 (100%)	4/5 (80%)	5/5 (100%)	2/2 (100%)	1/2 (50%)	0/2 (0%)
Cefotaxime	22/22 (100%)	3/4 (75%)	2/2 (100%)	2/2 (100%)	—	0/1 (0%)
Vancomycin	22/22 (100%)	4/4 (100%)	—	—	—	—
Clindamycin	7/7 (100%)	7/7 (100%)	—	—	—	—
Cefuroxime	2/2 (100%)	—	—	—	—	—
Meropenem/ Imipenem	—	—	2/2 (100%)	3/3 (100%)	2/2 (100%)	2/2 (100%)
Ciprofloxacin	—	3/3 (100%)	3/3 (100%)	—	2/2 (100%)	1/1 (100%)
Amikacin	—	—	—	2/2 (100%)	1/1 (100%)	1/1 (100%)
Chloramphenicol	7/7 (100%)	1/1 (100%)	0/1 (0%)	—	0/1 (0%)	—
Erythromycin	17/19 (89%)	5/8 (63%)	—	—	—	—
Amoxicillin/ Ampicillin	16/20 (80%)	3/8 (38%)	1/4 (25%)	0/1 (0%)	0/1 (0%)	0/2 (0%)
Oxacillin	14/22 (64%)	0/1 (0%)	—	—	—	—
Gentamicin	—	3/5 (60%)	3/4 (75%)	1/2 (50%)	2/3 (67%)	0/2 (0%)
Penicillin G	11/19 (58%)	0/2 (0%)	—	—	—	—
Cotrimoxazole	1/22 (5%)	0/8 (0%)	1/3 (33%)	0/2 (0%)	0/1 (0%)	0/1 (0%)

*Minimum inhibitory concentrations in $\mu\text{g/mL}$ used for classifying *S. pneumoniae* as susceptible or resistant were as follows: cefotaxime – 0.5; vancomycin – 0.5; meropenem – 0.13; chloramphenicol – 2; erythromycin – 0.06; amoxicillin – 0.25; gentamicin – 250; penicillin G – 0.03 and cotrimoxazole – 2/38.

children has significantly declined in the ART era.^{13,27} However, in a study from South Africa, the risk of invasive pneumococcal disease still remained 42-fold greater in HIV-infected compared with HIV-uninfected children.¹³ This is probably because of the incomplete immune reconstitution after initiation of ART²⁷ together with an irreversible loss of IgD+ memory B cells.²⁸ Therefore, it is important to prevent pneumococcal bacteremia if morbidity and mortality among HIV-infected children are to be reduced. Strategies that have been shown to be effective in achieving this goal include chemoprophylaxis with drugs such as penicillin and vaccination.^{29,30}

We found only 1 isolate of *H. influenzae*, likely due to routine HiB vaccination in Uganda and Zimbabwe; by contrast, the high rate of *S. pneumoniae* isolation was probably because pneumococcal vaccination is not currently routine in either country.^{31,32} In a randomized double-blind trial using the 9-valent pneumococcal conjugate vaccine among HIV-infected and HIV-uninfected children in South Africa, the incidence of invasive pneumococcal disease was significantly reduced among both groups of children receiving the vaccine.³⁰ However, the qualitative immune responses to 9-valent pneumococcal conjugate vaccine were poorer among the HIV-infected children.³³ Furthermore, whereas the long-term immunogenicity and efficacy of the vaccine persisted in the HIV uninfected, it greatly declined in the HIV-infected children.³⁴ This is probably because HIV-infected children lose anamnestic responses to pneumococcal vaccines and have early loss of memory B cell populations that are important for the generation of pneumococcal-specific responses.³⁵ However, it should be noted that majority of the children in these South African studies were not on ART; only 22.5% of the children received ART in the long term. Another South African study including ART-treated HIV-infected children (over 60% on ART) as well as HIV-uninfected infants³⁶ showed that the timing of ART initiation did not affect quantitative antibody responses between the HIV-infected children receiving ART and the HIV-infected children not on ART, but the children who were not receiving ART had more functionally impaired antibody responses measured by opsonophagocytic activity. Furthermore, results from a recent adult study³⁷ suggest that serological response to the vaccine could be better on ART. It is therefore expected that ART initiation would improve the response of HIV-infected children to the pneumococcal vaccine, although further research is

warranted into the optimal timing and frequency of booster doses of the vaccine in children.

Among HIV-infected children, the only current WHO-recommended antibiotic that is widely used for chemoprophylaxis is cotrimoxazole.³⁸ In our study, we found high rates of resistance of *S. pneumoniae* to cotrimoxazole and moderately high resistance to penicillin G. It is possible that cotrimoxazole prevented occurrence of some infections and that those we observed in this substudy were caused by drug-resistant strains. However, given that the morbidity caused by these resistant strains was high, there is need for more effective antibiotic choices in HIV-infected children, in order to increase prophylaxis against *S. pneumoniae* and widen protection against other pathogens frequently isolated from children with bacteremia. Azithromycin, a semisynthetic macrolide, is active against gram-positive organisms such as *S. pneumoniae*, *S. aureus*, *Streptococcus pyogenes* and *S. viridans*, and several gram-negative organisms including *Salmonella* spp.³⁹ It may therefore be an appropriate antibiotic for use in HIV-infected children in sub-Saharan Africa, given the bacterial isolates found by several investigators.^{12,14,15} Considering that azithromycin is administered orally and once daily, and also has activity against mycobacterium avium complex disease, it could be suitable for use on a large scale. However, given that this would certainly raise concerns about development of resistance,^{40,41} its use in prophylaxis against bacterial and other infections would be best evaluated in the most highly vulnerable HIV-infected individuals with very low CD4 counts/percentages at ART initiation and should be given for a limited period only. The Reduction of EARly mortalITy in HIV infected adults and children starting antiretroviral therapy (REALITY) trial (ISRCTN43622374), which is exploring short-term interventions at ART initiation to reduce early mortality in very immunosuppressed HIV-infected adults and children, will include azithromycin in its evaluation of a package of anti-infective interventions. Considering the role of cotrimoxazole in reducing morbidity and mortality among HIV-infected individuals even in places with high antibacterial resistance to the drug,^{42,43} any prophylactic agent against bacteremia should be in addition to cotrimoxazole.

The start of ART in a South African trial¹² was associated with an increase in the incidence of bacteremia among HIV-infected

children 8 months to 12 years, when compared with children not yet on ART; the incidence dropped significantly (by 74%) once children were established on ART. Our study showed a more dramatic 20-fold decrease in positive culture rates after 12 months on ART when compared with the first 3 months on ART, paralleling the improvement in CD4 count and percentage. Starting ART at higher CD4 counts/percentages therefore would also be likely to reduce the risk of children developing bacteremia after ART initiation. As expected, we also found that children with febrile illness and possible bacteremia were younger than other trial participants, suggesting that any interventions against bacteremia should also target younger HIV-infected children.

We isolated ESBL-producing *K. pneumoniae* from several children in ARROW. As had been observed in South Africa, isolation was not associated with prior hospitalization,¹⁴ implying that they were likely to be community acquired, which is a worrying trend.

We report isolation of *S. haemolyticus* and *S. hominis* that are known to be normal skin flora, and it is possible they were contaminants. However, these organisms together with coagulase-negative *Staphylococcus epidermidis* have been reported to cause bacteremia and sepsis among immunocompromised patients,^{44,45} such as those participating in this study. We also report the isolation of streptococcal spp other than *S. pneumoniae*, as well as other bacteria of doubtful pathogenicity. Given that the children had clinical symptoms, further research into their pathogenicity among HIV-infected children is warranted. Although children from whom blood cultures were taken presented with varied provisional diagnoses (including urinary tract infection, otitis media, malnutrition, respiratory tract infections and bacteremia), all had 1 common feature—fever. This implies that the rates of bacteremia and pattern of the isolated pathogens refer to febrile illnesses in general rather than specific syndromes.

The culture positivity rates were higher in Zimbabwe than at the Ugandan sites, probably because of the differential contribution of malaria to febrile illnesses across the sites. Whereas the whole of Uganda is endemic for malaria⁴⁶; Harare has no malaria.⁴⁷ This implies that among febrile illnesses, bacteremia was more likely in Harare than at the Ugandan sites because of the absence of malaria that contributed to the febrile episodes at the Ugandan sites. Although there was a difference in the methods of isolation, this is an unlikely explanation for the differential isolation rates, and the pattern of isolated pathogens was similar across sites. A limitation of this study is that we were not able to test the susceptibility profiles of all the isolates to the same antimicrobial agents, and in several cases, the numbers tested for certain antibiotics against particular isolates were small.

In summary, we observed high rates of proven bacteremia in HIV-infected children in the first 3 months on ART, with *S. pneumoniae* most commonly isolated. This reaffirms the need to incorporate pneumococcal vaccination in national immunization programs. The low susceptibility rates observed among isolated pathogens to cotrimoxazole suggest that alternative prophylactic antibiotic strategies need evaluation, including which populations to target and when. The results of our study suggest that the period immediately after ART initiation should be a period where targeted prophylaxis could be of benefit.

ACKNOWLEDGMENTS

The authors would like to thank all the children, their caregivers and staff from all the centers participating in the ARROW trial.

Joint Clinical Research Centre, Kampala, Uganda: P. Mugenyi, V. Musiime, R. Keishanyu, V. D. Afayo, J. Bwomezi, J. Byaruhanga,

P. Erimu, C. Karungi, H. Kizito, W. S. Namala, J. Namusanje, R. Nandugwa, T. K. Najjuko, E. Natukunda, M. Ndigendawani, S. O. Nsiyona, K. Robinah, M. Ssenyonga, D. Sseremba, J. Tezikyabbiri, C. S. Tumusiime, A. Balaba, A. Mugumya.

MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda: P. Munderi, P. Nahirya-Ntege, M. Aber, F. N. Kaggwa, P. Kaleebu, R. Katuramu, J. H. Kyarimpa, J. Lutaakome, L. Matama, M. Musinguzi, G. Nabulime, A. Ruberantwari, R. Sebukyu, I. M. Ssekamate, G. Tushabe, D. Wangi.

University of Zimbabwe, Harare, Zimbabwe: K. J. Nathoo, M. F. Bwakura-Dangarembizi, F. Mapepe, T. Mhute, T. Vhembo, R. Mandidewa, D. Nyoni, G. C. Tinago, J. Bhiri, D. Muchabaiwa, S. Mudzingwa, M. Phiri, C. C. Marozva, S. J. Maturure, L. Matanhike, S. Tsikirayi, L. Munetsi, K. M. Rashirai, J. Steamer, R. Nhema, W. Bikwa, B. Tambawoga, E. Mufuka, A. Sihole.

Mulago Hospital, Paediatric Infectious Diseases Clinic/Baylor-Uganda, Kampala, Uganda: A. Kekitiinwa, P. Musoke, S. Bakeera-Kitaka, R. Namuddu, P. Kasirye, JK Balungi, A. Babirye, J. Asello, S. Nakalanzi, NC Ssemambo, J. Nakafeero, J. Tikabibamu, G. Musoba, J. Ssanyu, M. Kisekka, S. Atukunda.

MRC Clinical Trials Unit, London, United Kingdom: D. M. Gibb, M. J. Thomason, A. S. Walker, A. D. Cook, B. Naidoo, M. J. Spyer, C. Male, A. J. Glabay, L. K. Kendall, A. J. Prendergast.

Independent ARROW Trial Monitors: I. Machingura, S. Ssenyonjo.

Trial Steering Committee: I. Weller (Chair), E. Luyirika, H. Lyall, E. Malianga, C. Mwansambo, M. Nyathi, F. Miiro, D. M. Gibb, A. Kekitiinwa, P. Mugenyi, P. Munderi, K. J. Nathoo. Observers: S. Kinn, M. McNeil, M. Roberts, W. Snowden.

Data and Safety Monitoring Committee: A. Breckenridge (Chair), A. Pozniak, C. Hill, J. Matenga, J. Tumwine, A. S. Walker.

Endpoint Review Committee: G. Tudor-Williams (Chair), H. Barigye, H. A. Mujuru, G. Ndeezi.

REFERENCES

- Bachou H, Tylleskär T, Kaddu-Mulindwa DH, et al. Bacteraemia among severely malnourished children infected and uninfected with the human immunodeficiency virus-1 in Kampala, Uganda. *BMC Infect Dis*. 2006;6:160.
- Campo RE, Campo CE, Peter G, et al. Differences in presentation and outcome of invasive pneumococcal disease among patients with and without HIV infection in the pre-HAART era. *AIDS Patient Care STDS*. 2005;19:141–149.
- Cohen C, Singh E, Wu HM, et al.; Group for Enteric, Respiratory and Meningeal disease Surveillance in South Africa (GERMS-SA). Increased incidence of meningococcal disease in HIV-infected individuals associated with higher case-fatality ratios in South Africa. *AIDS*. 2010;24:1351–1360.
- Karstaedt AS, Khoosal M, Crewe-Brown HH. Pneumococcal bacteremia during a decade in children in Soweto, South Africa. *Pediatr Infect Dis J*. 2000;19:454–457.
- Nathoo KJ, Chigonde S, Nhembe M, et al. Community-acquired bacteremia in human immunodeficiency virus-infected children in Harare, Zimbabwe. *Pediatr Infect Dis J*. 1996;15:1092–1097.
- Netsawang S, Punpanich W, Treeratweeraphong V, et al. Invasive pneumococcal infection in urban Thai children: a 10-year review. *J Med Assoc Thai*. 2010;93(suppl 5):S6–S12.
- Noel F, Wright PF, Bois G, et al. Contribution of bacterial sepsis to morbidity in infants born to HIV-infected Haitian mothers. *J Acquir Immune Defic Syndr*. 2006;43:313–319.
- Nyasulu P, Cohen C, De Gouveia L, et al. Increased risk of death in human immunodeficiency virus-infected children with Pneumococcal Meningitis in South Africa, 2003–2005. *Pediatr Infect Dis J*. 2011;30:1075–1080.
- Hatherill M. Sepsis predisposition in children with human immunodeficiency virus. *Pediatr Crit Care Med*. 2005;6(suppl 3):S92–S98.
- Kapogiannis BG, Soe MM, Nesheim SR, et al. Trends in bacteremia in the pre- and post-highly active antiretroviral therapy era among HIV-infected

- children in the US Perinatal AIDS Collaborative Transmission Study (1986-2004). *Pediatrics*. 2008;121:e1229-e1239.
11. Steenhoff AP, Wood SM, Rutstein RM, et al. Invasive pneumococcal disease among human immunodeficiency virus-infected children, 1989-2006. *Pediatr Infect Dis J*. 2008;27:886-891
 12. le Roux DM, Cotton MF, le Roux SM, et al. Bacteremia in human immunodeficiency virus-infected children in Cape Town, South Africa. *Pediatr Infect Dis J*. 2011;30:904-906.
 13. Nunes MC, von Gottberg A, de Gouveia L, et al. The impact of antiretroviral treatment on the burden of invasive pneumococcal disease in South African children: a time series analysis. *AIDS*. 2011;25:453-462.
 14. Cotton MF, Wasserman E, Smit J, et al. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing Enterobacteriaceae and methicillin-resistant *Staphylococcus aureus* in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. *BMC Infect Dis*. 2008;8:40.
 15. Feikin DR, Jagero G, Aura B, et al. High rate of pneumococcal bacteremia in a prospective cohort of older children and adults in an area of high HIV prevalence in rural western Kenya. *BMC Infect Dis*. 2010;10:186.
 16. Babirekere-Iriso E, Musoke P, Kekitinwa A. Bacteraemia in severely malnourished children in an HIV-endemic setting. *Ann Trop Paediatr*. 2006;26:319-328.
 17. BD. BD bactec instrumented blood culture systems. Available at: www.bd.com. Accessed September 19, 2011.
 18. Turng BVM, Turner D, Pollitt J, et al. *Detection of Extended Beta - lactamase among Enterobacteriaceae using Phoenix TM automated microbiology system with BDxpertTM system In: Interscience Conference on Antimicrobial agents and Chemotherapy (ICAAC)*. San Diego, CA; 2002. Available at: <http://www.infectweb.com/only/nwsrpt15.htm>. Accessed June 26, 2013.
 19. CSLI. Clinical laboratory standards institute antimicrobial susceptibility testing. Available at: www.csl.org. Accessed September 19, 2011.
 20. Smith PB, Tomfohrde KM, Rhoden DL, et al. API system: a multitube micromethod for identification of Enterobacteriaceae. *Appl Microbiol*. 1972;24:449-452.
 21. Bauer AW, Kirby WM, Sherris JC, et al. Antibiotic susceptibility testing by a standardized single disk method. *Am J Clin Pathol*. 1966;45:493-496.
 22. BSAC. BSAC susceptibility testing guide. Available at: [bsac.org.uk](http://www.bsac.org.uk). Accessed September 19, 2011.
 23. Mugenyi P, Walker AS, Hakim J, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. *Lancet*. 2010;375:123-131.
 24. Walker AS, Prendergast AJ, Mugenyi P, et al.; DART and ARROW trial teams. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. *Clin Infect Dis*. 2012;55:1707-1718.
 25. Poon LM, Jin J, Chee YL, et al. Risk factors for adverse outcomes and multidrug-resistant Gram-negative bacteraemia in haematology patients with febrile neutropenia in a Singaporean university hospital. *Singapore Med J*. 2012;53:720-725.
 26. Aiken AM, Mturi N, Njuguna P, et al.; Kilifi Bacteraemia Surveillance Group. Risk and causes of paediatric hospital-acquired bacteraemia in Kilifi District Hospital, Kenya: a prospective cohort study. *Lancet*. 2011;378:2021-2027.
 27. Heffernan RT, Barrett NL, Gallagher KM, et al. Declining incidence of invasive *Streptococcus pneumoniae* infections among persons with AIDS in an era of highly active antiretroviral therapy, 1995-2000. *J Infect Dis*. 2005;191:2038-2045.
 28. Jacobsen MC, Thiébaud R, Fisher C, et al. Pediatric human immunodeficiency virus infection and circulating IgD+ memory B cells. *J Infect Dis*. 2008;198:481-485.
 29. Gaston MH, Verter JJ, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *N Engl J Med*. 1986;314:1593-1599.
 30. Klugman KP, Madhi SA, Huebner RE, et al.; Vaccine Trialists Group. A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. *N Engl J Med*. 2003;349:1341-1348.
 31. Ministry of Health Uganda. UNEPI standards. First edition, 2003. Available at: <http://www.basics.org/documents/pdf/UNEP1%20Standards.pdf>. Accessed October 19, 2011.
 32. WHO. Immunization profile_Zimbabwe. Available at: http://apps.who.int/immunization_monitoring/en/globalsummary/countryprofilresult.cfm?C=zwe. Accessed October 19, 2011.
 33. Madhi SA, Kuwanda L, Cutland C, et al. Quantitative and qualitative antibody response to pneumococcal conjugate vaccine among African human immunodeficiency virus-infected and uninfected children. *Pediatr Infect Dis J*. 2005;24:410-416.
 34. Madhi SA, Adrian P, Kuwanda L, et al. Long-term immunogenicity and efficacy of a 9-valent conjugate pneumococcal vaccine in human immunodeficient virus infected and non-infected children in the absence of a booster dose of vaccine. *Vaccine*. 2007;25:2451-2457.
 35. Madhi SA, Klugman KP, Kuwanda L, et al. Quantitative and qualitative anamnestic immune responses to pneumococcal conjugate vaccine in HIV-infected and HIV-uninfected children 5 years after vaccination. *J Infect Dis*. 2009;199:1168-1176.
 36. Madhi SA, Adrian P, Cotton MF, et al.; Comprehensive International Program of Research on AIDS 4 Study Team. Effect of HIV infection status and anti-retroviral treatment on quantitative and qualitative antibody responses to pneumococcal conjugate vaccine in infants. *J Infect Dis*. 2010;202:355-361.
 37. Lu CL, Hung CC, Chuang YC, et al. Serologic response to primary vaccination with 7-valent pneumococcal conjugate vaccine is better than with 23-valent pneumococcal polysaccharide vaccine in HIV-infected patients in the era of combination antiretroviral therapy. *Hum Vaccin Immunother*. 2013;9:398-404.
 38. WHO. Antiretroviral therapy for HIV infection in infants and children; towards universal access: recommendations for a public health approach: 2010 revision [2010]. Available at: <http://www.who.int/hiv/pub/paediatric/infants>. Accessed September 30, 2011.
 39. Gold-Standard. Azithromycin. Available at: <http://www.answers.com/topic/azithromycin-oral-suspension>. Accessed March 26, 2012.
 40. Dagan R, Barkai G, Leibovitz E, et al. Will reduction of antibiotic use reduce antibiotic resistance?: The pneumococcus paradigm. *Pediatr Infect Dis J*. 2006;25:981-986.
 41. Leach AJ, Shelby-James TM, Mayo M, et al. A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of *Streptococcus pneumoniae*. *Clin Infect Dis*. 1997;24:356-362.
 42. Chintu C, Bhat GJ, Walker AS, et al.; CHAP trial team. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. *Lancet*. 2004;364:1865-1871.
 43. Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. *Lancet*. 2004;364:1428-1434.
 44. Sloos JH, Dijkshoorn L, van Boven CP. Septicaemias caused by a strain of *Staphylococcus haemolyticus* exhibiting intermediate susceptibility to teicoplanin in multiple intensive care unit patients. *J Antimicrob Chemother*. 2000;45:410-411.
 45. Weinstein MP, Mirrett S, Van Pelt L, et al. Clinical importance of identifying coagulase-negative staphylococci isolated from blood cultures: evaluation of MicroScan Rapid and Dried Overnight Gram-Positive panels versus a conventional reference method. *J Clin Microbiol*. 1998;36:2089-2092.
 46. WHO-Roll-back-Malaria. *Malaria Endemic Countries*. 2010. Available at: www.rbm.who.int/endemiccountries.html. Accessed December 2, 2012.
 47. fitfortravel. Zimbabwe Malaria. Available at: <http://www.fitfortravel.nhs.uk/destinations/africa/zimbabwe/zimbabwe-malaria-map.aspx>. Accessed December 1, 2012.